Showing results (81-90 of 264) with videos related to
Sort By:
Pageof 27
The Journal of Experimental Medicine|January 1, 1982
Postnatal expansion of the natural killer and keller cell population in humans identified by the monoclonal HNK-1 antibodyT Abo, M D Cooper, C M BalchCellular Immunology|September 1, 1987
Spontaneous human T-cell cytotoxicity against murine hybridomas expressing the OKT3 monoclonal antibody: comparison with natural killer cell activityK Itoh, C M Balch, C D PlatsoucasJournal of Immunology (Baltimore, Md. : 1950)|February 15, 1987
Human lymphokine-activated killer (LAK) cells: identification of two types of effector cellsA B Tilden, K Itoh, C M BalchSeminars in Surgical Oncology|May 1, 1993
Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanomaM I Ross, D Reintgen, C M BalchArchives of Surgery (Chicago, Ill. : 1960)|September 1, 1989
Patterns of relapse in 1001 consecutive patients with melanoma nodal metastasesA Calabro, S E Singletary, C M BalchJournal of the American Academy of Dermatology|August 1, 1997
Eruptive melanocytic nevi after Stevens-Johnson syndromeT Shoji, C J Cockerell, A B Koff, et al.Surgery|August 1, 1985
Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factorC M Balch, K Itoh, A B TildenJournal of Immunology (Baltimore, Md. : 1950)|May 15, 1986
Lysis of human solid tumor cells by lymphokine-activated natural killer cellsK Itoh, A B Tilden, C M BalchThe Journal of Experimental Medicine|October 1, 1988
Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptorK Itoh, C D Platsoucas, C M BalchAnnals of Surgery|August 1, 1983
The impact of surgical quality control in multi-institutional group trials involving adjuvant cancer treatmentsC M Balch, J R Durant, A A BartolucciPageof 27